Neuland Laboratories Q2 FY26 Financial Results

Neuland Laboratories Ltd. has delivered a record-breaking performance for the second quarter of the fiscal year 2026, ending September 30, 2025. The results demonstrate significant year-on-year growth, driven by strong operational execution and robust demand in the Custom Manufacturing Solutions (CMS) segment. Key Financial Highlights (Q2 FY26 vs. Q2 FY25) Net Profit: A 166% increase to ₹129 crore, up from ₹48.5 crore. Revenue from Operations: A 63.7% increase to ₹516 crore, up from ₹315.2 crore. EBITDA: A 138.8% increase to ₹156.9 crore, up from ₹65.7 crore. EBITDA Margin: Significant expansion to 30.4%, compared to 20.8% in the prior-year period. Management Commentary & Business Outlook The quarter's exceptional revenue growth, primarily fueled by CMS commercial projects, has resulted in significant operating leverage and the highest-ever EBITDA margins. Sucheth Davuluri, Vice-Chairman and CEO, noted that the company anticipates this positive momentum will continue through the remainder of the fiscal year. Strategic investments are positioning Neuland to effectively capture growth opportunities across both the CDMO (Contract Development and Manufacturing Organization) and generic APIs (Active Pharmaceutical Ingredients) verticals. Saharsh Davuluri, Vice Chairman and Managing Director, highlighted that customer interest in Neuland's capabilities is accelerating. The company's established reputation as an agile and reliable partner is proving instrumental in securing new business and expanding its "share of wallet" with existing clients. He confirmed that strategic investments are progressing as planned, further differentiating Neuland as a partner of choice in the pharmaceutical industry. This strong quarterly performance underscores the success of our strategic focus and our enhanced position in the global market.